ArticleJournal of immunological methods2008
Engineering higher affinity T cell receptors using a T cell display system.
Article in Journal of immunological methods, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 66 citations in OpenAlex.
- Mechano-pharmacology of T cell receptor specificity.Cell research · 2025Article
- Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects.Frontiers in immunology · 2024Review
- ReliableJournal of chemical information and modeling · 2022Article
- Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle.Therapeutic advances in medical oncology · 2022Review
- Engineering soluble T-cell receptors for therapy.The FEBS journal · 2021Review
- An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML.Cancers · 2021Article
- Avidity optimization of a MAGE-A1-specific TCR with somatic hypermutation.European journal of immunology · 2021Article
- Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy.Molecular therapy oncolytics · 2020Article
- Review
- Review
- Stabilization of soluble high-affinity T-cell receptor with de novo disulfide bonds.FEBS letters · 2020Article
- Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.Frontiers in immunology · 2020Review
- T-cell Receptors EngineeredCancer immunology research · 2019Article
- Induced Pluripotent Stem Cell-Derived T Cells for Cancer Immunotherapy.Surgical oncology clinics of North America · 2019Review
- Weaponizing T-cell receptors through molecular engineering.The Journal of biological chemistry · 2019Article
- Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display.The Journal of biological chemistry · 2019Article
- Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro.Nature biotechnology · 2017Article
- Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex.The Journal of biological chemistry · 2016Article
- T-cell receptor gene therapy--ready to go viral?Molecular oncology · 2015Review
- T cell engineering as therapy for cancer and HIV: our synthetic future.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The T cell receptor (TCR) determines the cellular response to antigens, which are presented on the surface of target cells in the form of a peptide bound to a product of the major histocompatibility complex (pepMHC). The response of the T cell depends on the affinity of the TCR for the pepMHC, yet many TCRs have been shown to be of low affinity, and some naturally occurring T cell responses are poor due to low affinities. Accordingly, engineering the TCR for increased affinity for pepMHC, particularly tumor-associated antigens, has become an increasingly desirable goal, especially with the advent of adoptive T cell therapies. For largely technical reasons, to date there have been only a handful of TCRs engineered in vitro for higher affinity using well established methods of protein engineering. Here we report the use of a T cell display system, using a retroviral vector, for generating a high-affinity TCR from the mouse T cell clone 2C. The method relies on the display of the TCR, in its normal, signaling competent state, as a CD3 complex on the T cell surface. A library in the CDR3alpha of the 2C TCR was generated in the MSCV retroviral vector and transduced into a TCR-negative hybridoma. Selection of a high-affinity, CD8-independent TCR was accomplished after only two rounds of flow cytometric sorting using the pepMHC SIYRYYGL/Kb (SIY/Kb). The selected TCR contained a sequence motif in the CDR3alpha with characteristics of several other TCRs previously selected by yeast display. In addition, it was possible to directly use the selected T cell hybridoma in functional assays without the need for sub-cloning, revealing that the selected TCR was capable of mediating CD8-independent activity. The method may be useful in the direct isolation and characterization of TCRs that could be used in therapies with adoptive transferred T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.